Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension
Ronald J. Raymond, MD*,
Alan L. Hinderliter, MD*,*,
Park W. Willis, IV, MD*,
David Ralph, MD ,
Edgar J. Caldwell, MD ,
William Williams, MD ,
Neil A. Ettinger, MD ,
Nicholas S. Hill, MD||,
Warren R. Summer, MD¶,
Bennett de Boisblanc, MD¶,
Todd Schwartz, MS#,
Gary Koch, PhD#,
Linda M. Clayton, Pharm D**,
Maria M. Jöbsis, BA**,
James W. Crow, PhD ,
Walker Long, MD Primary Pulmonary Hypertension Study Group
* University of North Carolina, Chapel Hill, North Carolina, USA
University of Washington, Seattle, Washington, USA
Maine Medical Center, Portland, Maine, USA
Washington University, St. Louis, Missouri, USA
|| Rhode Island Hospital, Providence, Rhode Island, USA
¶ Louisiana State University Medical Center, New Orleans, Louisana, USA
# Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina, USA
** GlaxoWellcome Inc., Research Triangle Park, North Carolina, USA
 United Therapeutics, Inc., Chapel Hill, North Carolina, USA
 Cato Research Ltd., Durham, North Carolina, USA

View larger version (17K):
[in a new window]
|
Figure 1 Kaplan-Meier survival curves for echocardiographic predictors of outcomes. By Cox proportional hazards modeling, right atrial (RA) area index (p = 0.005) and pericardial effusion (p = 0.003) were significant predictors of death; the relationship of diastolic eccentricity index to mortality was of marginal statistical significance (p = 0.074). Right atrial area index (p = 0.012), pericardial effusion (p = 0.017) and diastolic eccentricity index (p = 0.004) were all significant predictors of a composite end point of death or transplantation.
|
|
|